N/A N=76 One Month Daily Wear Clinical Evaluation of New Prototype Contact Lenses in Habitual and Neophyte Contact Lens Wearers
Visual Correction
Primary: Corneal Staining (Area) — 11.76; 5.79; 4.17; 6.18 Units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=10 Global Vascular Effects of Intermittent Pneumatic Compression-Pilot Study
Coronary Heart Disease
Primary: Brachial Flow Velocity — 21.0 cm/sec
Phase 3 N=128 Vitamin D and Arterial Function in Patients With Chronic Kidney Disease
Arterial Dysfunction · Chronic Kidney Disease
Primary: Compare the Difference Between the Calcitriol and Cholecalciferol Groups in Conduit Artery Endothelium-dependent Dilation (EDD) in Response to Treatment. — -0.5; 0.3…
N/A N=19 Avastin for PDR (Proliferative Diabetic Retinopathy)
Retinal Detachment · Diabetic Retinopathy
Primary: The Effect of an Anti-VEGF (Vascular Endothelial Growth Factor) Agent, Bevacizumab, on Levels of Vitreous and Aqueous Growth Factor Levels (pg/mL) in Eyes With Traction…
Phase 2 N=28 Effects of Ibudilast on Oxycodone Self-administration in Opioid Abusers
Opioid Abuse · Opioid Dependence
Primary: Drug Self-administration Breakpoint — 347; 363; 1472; 43 Clicks on a computer mouse
Phase 3 N=81 Psychosocial and Medication Treatment for Anxiety in Alcoholism
Alcohol-Related Disorders · Anxiety Disorders
Primary: Clinical Global Impression Scale-I (CGI-I) — 3.65; 3.81; 3.86; 4.05 units on a scale
Phase 2 N=14 Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)
Vestibular Schwannoma · Neurofibromatosis Type 2
Primary: Proportion of Patients With Hearing Response — 0.36; 0.50 Proportion with hearing response
N/A N=17 Clinical Study of Asahi ViE Dialyzer in Canada
Kidney Failure, Chronic
Primary: Removal Rate of Urea — 76.1; 74.4; 73.5 percentage of urea removal
N/A N=40 PRESERVE-Zenith® Iliac Branch System Clinical Study
Aorto-iliac Aneurysms · Iliac Aneurysms
Primary: Patients That Are Free From Patency-related Intervention — 33 participants
Phase 3 N=394 A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis
Postmenopausal Osteoporosis
Primary: Percent Change From Baseline in Lumbar Spine BMD — 5.78; 5.73 percent change — p=< 0.001
Phase 3 N=57 Topiramate Alone and in Combination With the Nicotine Patch for Smoking Cessation: A Pilot Study
Tobacco Dependence
Primary: Primary Outcome is 4-week Continuous Quit Rate at the End of Treatment. — 1; 5; 7 Participants
N/A N=21 Stage 3 Fontan Operation Liver Ultrasound Study
Fontan Operation
Primary: Shear Wave Speed (Liver Stiffness) — 1.18; 2.28; 2.22; 2.08 meters per second — p=<0.0001
Phase 2 N=15 Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 in Type 2 Diabetes Patients Taking Metformin
Diabetes Mellitus, Type 2
Primary: Number of Participants With at Least One Adverse Event (AE), Serious Adverse Event (SAE) or Death — 12; 9; 1; 0 Participants
Phase 2 N=39 Baclofen for Treating Anxiety and Alcoholism
Alcoholism · Alcohol Dependence · Alcohol Drinking Related Problems
Primary: Total Amount of Alcohol Consumed During the Alcohol Self Administration (ASA) Session — 4.11; 4.5 mini-drinks
N/A N=67 Employment-based Reinforcement of Naltrexone Ingestion and Abstinence
Cocaine-Related Disorders · Heroin Dependence · Opioid-Related Disorders
Primary: Percentage of Urine Samples Positive for Naltrexone — 21; 72 Percentage of Urine Samples — p=<0.01